Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. / Mensberg, Pernille; Nyby, Signe; Jørgensen, Peter Godsk; Storgaard, H; Jensen, Magnus Thorsten; Sivertsen, J; Holst, Jens Juul; Kiens, Bente; Richter, Erik A.; Knop, Filip Krag; Lauritsen, Tina Vilsbøll.
I: Diabetes, Obesity and Metabolism, Bind 19, Nr. 2, 2017, s. 172-180.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes
AU - Mensberg, Pernille
AU - Nyby, Signe
AU - Jørgensen, Peter Godsk
AU - Storgaard, H
AU - Jensen, Magnus Thorsten
AU - Sivertsen, J
AU - Holst, Jens Juul
AU - Kiens, Bente
AU - Richter, Erik A.
AU - Knop, Filip Krag
AU - Lauritsen, Tina Vilsbøll
N1 - CURIS 2017 NEXS 036
PY - 2017
Y1 - 2017
N2 - Aims: Exercise as well as glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment improves glycaemic control in patients with type 2 diabetes. We investigated the effects of exercise in combination with a GLP-1RA (liraglutide) or placebo for the treatment of type 2 diabetes.Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training.Results: HbA1c levels dropped by 2.0 ± 1.2% (mean ± standard deviation) (from 8.2 ± 1.4%) in the exercise plus liraglutide group vs 0.3 ± 0.9% (from 8.0 ± 1.2%) with exercise plus placebo (p < 0.001), and body weight was reduced more with liraglutide (-3.4 ± 2.9 vs -1.6 ± 2.3 kg, p < 0.001). Compared to baseline, similar reductions were seen in body fat (exercise plus liraglutide: -2.5 ± 1.4%, (p < 0.001); exercise plus placebo: -2.2 ± 1.9%, (p < 0.001)) and similar increases were observed in maximal oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 l O2 per min (p < 0.001); exercise plus placebo: 0.4 ± 0.4 l O2 per min (p = 0.002)). Greater reductions in fasting plasma glucose (-3.4 ± 2.3 vs -0.3 ± 2.6 mM, p < 0.001) and systolic blood pressure (-5.4 ± 7.4 vs -0.6 ± 11.1 mmHg, p < 0.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention.Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalised HbA1c levels and caused a robust weight loss when compared to placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.
AB - Aims: Exercise as well as glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment improves glycaemic control in patients with type 2 diabetes. We investigated the effects of exercise in combination with a GLP-1RA (liraglutide) or placebo for the treatment of type 2 diabetes.Methods: Thirty-three overweight, dysregulated and sedentary patients with type 2 diabetes were randomly allocated to 16 weeks of exercise and liraglutide or exercise and placebo. Both groups had three supervised 60-minute training sessions per week including spinning and resistance training.Results: HbA1c levels dropped by 2.0 ± 1.2% (mean ± standard deviation) (from 8.2 ± 1.4%) in the exercise plus liraglutide group vs 0.3 ± 0.9% (from 8.0 ± 1.2%) with exercise plus placebo (p < 0.001), and body weight was reduced more with liraglutide (-3.4 ± 2.9 vs -1.6 ± 2.3 kg, p < 0.001). Compared to baseline, similar reductions were seen in body fat (exercise plus liraglutide: -2.5 ± 1.4%, (p < 0.001); exercise plus placebo: -2.2 ± 1.9%, (p < 0.001)) and similar increases were observed in maximal oxygen uptake (exercise plus liraglutide: 0.5 ± 0.5 l O2 per min (p < 0.001); exercise plus placebo: 0.4 ± 0.4 l O2 per min (p = 0.002)). Greater reductions in fasting plasma glucose (-3.4 ± 2.3 vs -0.3 ± 2.6 mM, p < 0.001) and systolic blood pressure (-5.4 ± 7.4 vs -0.6 ± 11.1 mmHg, p < 0.01) were seen with exercise plus liraglutide vs exercise plus placebo. The two groups experienced similar increases in quality of life during the intervention.Conclusions: In obese patients with type 2 diabetes, exercise combined with GLP-1RA treatment near-normalised HbA1c levels and caused a robust weight loss when compared to placebo. These results suggest that a combination of exercise and GLP-1RA treatment is effective in type 2 diabetes.
KW - Faculty of Science
KW - Exercise
KW - GLP-1
KW - GLP-1 receptor agonist
KW - Glucagon-like peptide-1
KW - Liraglutide
KW - Randomized study
KW - Type 2 diabetes
U2 - 10.1111/dom.12797
DO - 10.1111/dom.12797
M3 - Journal article
C2 - 27717126
VL - 19
SP - 172
EP - 180
JO - Diabetes, Obesity and Metabolism
JF - Diabetes, Obesity and Metabolism
SN - 1462-8902
IS - 2
ER -
ID: 167474168